Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

NCT04952766 is registered in ClinicalTrials.gov with Centre Hospitalier Régional d'Orléans as lead sponsor.

NCT NCT04952766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Lead sponsor
Centre Hospitalier Régional d'Orléans
Phase
Phase 4
Overall status
Completed
Start date
March 26, 2021
Completion date
February 6, 2022
Enrollment
196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, diabetes type 2, hematologic malignancy, hiv, hypergammaglobulinemia, kidney transplant, malignant tumor, multiple sclerosis, myeloma